Although the aforementioned studies indicate that USP22 is a GC oncogene, a meta-analysis noted contradictions between USP22 expression, tumor size, differentiation state, tumor stage, and clinical outcomes in patients with gastric tumors. This evidence concerns the gene USP22 and neoplasm.